SCHEMBL5363322

SCHEMBL5363322

COC(=O)C(C)(C)C(O)c1ccc(Cl)nc1NC(=O)C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ HTT P42858 1/20 0.33
▸ PAX8 Q06710 1/20 0.32
▸ ATM Q13315 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ MAPT P10636 2/20 0.32
▸ ADORA1 P30542 1/20 0.32
▸ F2 P00734 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ CNR1 P21554 1/20 0.31
▸ CNR2 P34972 1/20 0.31
▸ CYP26A1 O43174 1/20 0.31
▸ KDM4E B2RXH2 3/20 0.31
▸ GAA P10253 1/20 0.31
▸ PARP2 Q9UGN5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5383471 0.78 LMNA (0.40) L3MBTL1ALDH1A1MEN1KMT2AHTT
SCHEMBL19691913 0.76 CTSA (0.39) L3MBTL1ALDH1A1MEN1KMT2AHTT
SCHEMBL5375594 0.75 KMT2A (0.34) L3MBTL1ALDH1A1MEN1KMT2AHTT
SCHEMBL30884722 0.74 PARP2 (0.45) L3MBTL1ALDH1A1MEN1KMT2AHTT
SCHEMBL1661669 0.73 KMT2A (0.47) L3MBTL1ALDH1A1MEN1KMT2AHTT
SCHEMBL267725 0.72 L3MBTL1 (0.44) L3MBTL1ALDH1A1MEN1KMT2AHTT
SCHEMBL3326127 0.71 L3MBTL1 (0.43) L3MBTL1ALDH1A1MEN1KMT2AHTT
SCHEMBL1047479 0.71 L3MBTL1 (0.43) L3MBTL1ALDH1A1MEN1KMT2AHTT
SCHEMBL5374156 0.70 L3MBTL1 (0.42) L3MBTL1ALDH1A1MEN1KMT2AHTT
SCHEMBL12780025 0.70 L3MBTL1 (0.42) L3MBTL1ALDH1A1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7160888-B2 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER LAMBERT COMPANY LLC (US) 2007-01-09 — — US disclosed
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 — — US disclosed
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 — — US disclosed
EP-1660497-A1 [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2006-05-31 — — EP disclosed
WO-2005019215-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2005-03-03 — — WO disclosed
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2005-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia DRD1, DRD2, DRD3 L3MBTL1 4010/4885ALDH1A1 1148/4885MEN1 3394/4885
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 L3MBTL1 4010/4885ALDH1A1 1148/4885MEN1 3394/4885
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 L3MBTL1 4010/4885ALDH1A1 1148/4885MEN1 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback